Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome

Neuroscience and Biobehavioral Reviews

Volumn 45, Issue , 2014, Pages 72-84

  Dekker, Alain D ^a,b   De Deyn, Peter P ^a,b   Rots, Marianne G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; DNA methylation; Down syndrome; Epigenetic Editing; Epigenetics; Gene expression; Mental retardation; Post translational histone modifications

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT; DNA; DONEPEZIL; LONG UNTRANSLATED RNA; MICRORNA;

BIPOLAR DISORDER; CANCER GENE THERAPY; CHROMOSOME 21; COGNITIVE DEFECT; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DOWN SYNDROME; EPIGENETICS; EPILEPSY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE THERAPY; GENETIC DISORDER; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; INTELLECTUAL IMPAIRMENT; LEARNING DISORDER; MEMORY DISORDER; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; CHROMATIN; CHROMATIN STRUCTURE; DISEASE ASSOCIATION; DRUG INDICATION; DRUG RESPONSE; EPIGENETIC EDITING; GENETIC REGULATION; GENETIC VARIABILITY; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; PROTEIN PHOSPHORYLATION; ALZHEIMER DISEASE; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; MEMORY DISORDERS; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DOWN SYNDROME; EPIGENESIS, GENETIC; HUMANS; MEMORY DISORDERS;

EID: 84901783922     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.05.004     Document Type: Review

References (149)

1. Abuhatzira L., Shamir A., Schones D.E., Schaffer A.A., Bustin M. The chromatin-binding protein HMGN1 regulates the expression of methyl CpG-binding protein 2 (MECP2) and affects the behavior of mice. J. Biol. Chem. 2011, 286:42051-42062.
2. Ait Yahya-Graison E., Aubert J., Dauphinot L., Rivals I., Prieur M., Golfier G., Rossier J., Personnaz L., Creau N., Blehaut H., Robin S., Delabar J.M., Potier M.C. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 2007, 81:475-491.
3. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., Oset M., Gonzalez J.R., Florez J., Fillat C., Estivill X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 2001, 10:1915-1923.
4. Altafaj X., Martin E.D., Ortiz-Abalia J., Valderrama A., Lao-Peregrin C., Dierssen M., Fillat C. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2013, 52:117-127.
5. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
6. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 2004, 5:725-738.
7. Arima T., Hata K., Tanaka S., Kusumi M., Li E., Kato K., Shiota K., Sasaki H., Wake N. Loss of the maternal imprint in Dnmt3Lmat-/- mice leads to a differentiation defect in the extraembryonic tissue. Dev. Biol. 2006, 297:361-373.
8. Bahn S., Mimmack M., Ryan M., Caldwell M.A., Jauniaux E., Starkey M., Svendsen C.N., Emson P. Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study. Lancet 2002, 359:310-315.
9. Bakshi R., Hassan M.Q., Pratap J., Lian J.B., Montecino M.A., van Wijnen A.J., Stein J.L., Imbalzano A.N., Stein G.S. The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J. Cell. Physiol. 2010, 225:569-576.
10. Barrett R.M., Wood M.A. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn. Mem. 2008, 15:460-467.
11. Bartholdi D., Roelfsema J.H., Papadia F., Breuning M.H., Niedrist D., Hennekam R.C., Schinzel A., Peters D.J. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300. J. Med. Genet. 2007, 44:327-333.
12. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer. 2011, 11:726-734.
13. Becker W., Joost H.G. Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog. Nucleic Acid Res. Mol. Biol. 1999, 62:1-17.
14. Berdasco M., Esteller M. Genetic syndromes caused by mutations in epigenetic genes. Hum. Genet. 2013, 132:359-383.
15. Berger S.L., Kouzarides T., Shiekhattar R., Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009, 23:781-783.
16. Bestor T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 2000, 9:2395-2402.
17. Bhartiya D., Pal K., Ghosh S., Kapoor S., Jalali S., Panwar B., Jain S., Sati S., Sengupta S., Sachidanandan C., Raghava G.P., Sivasubbu S., Scaria V. lncRNome: a comprehensive knowledgebase of human long noncoding RNAs. Database (Oxford) 2013, 2013:bat034.
18. Bittles A.H., Bower C., Hussain R., Glasson E.J. The four ages of Down syndrome. Eur. J. Public Health 2007, 17:221-225.
19. Bourc'his D., Xu G.L., Lin C.S., Bollman B., Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science 2001, 294:2536-2539.
20. Braudeau J., Dauphinot L., Duchon A., Loistron A., Dodd R.H., Herault Y., Delatour B., Potier M.C. Chronic treatment with a promnesiant GABA-A alpha5-selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down syndrome mouse model. Adv. Pharmacol. Sci. 2011, 2011:153218.
21. Brink M.C., Piebes D.G., de Groote M.L., Luijsterburg M.S., Casas-Delucchi C.S., van Driel R., Rots M.G., Cardoso M.C., Verschure P.J. A role for MeCP2 in switching gene activity via chromatin unfolding and HP1gamma displacement. PLoS ONE 2013, 8:e69347.
22. Canzonetta C., Mulligan C., Deutsch S., Ruf S., O'Doherty A., Lyle R., Borel C., Lin-Marq N., Delom F., Groet J., Schnappauf F., De Vita S., Averill S., Priestley J.V., Martin J.E., Shipley J., Denyer G., Epstein C.J., Fillat C., Estivill X., Tybulewicz V.L., Fisher E.M., Antonarakis S.E., Nizetic D. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am. J. Hum. Genet. 2008, 83:388-400.
23. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000, 157:277-286.
24. Cetin Z., Yakut S., Mihci E., Manguoglu A.E., Berker S., Keser I., Luleci G. A patient with Down syndrome with a de novo derivative chromosome 21. Gene 2012, 507:159-164.
25. Chango A., Abdennebi-Najar L., Tessier F., Ferre S., Do S., Gueant J.L., Nicolas J.P., Willequet F. Quantitative methylation-sensitive arbitrarily primed PCR method to determine differential genomic DNA methylation in Down syndrome. Biochem. Biophys. Res. Commun. 2006, 349:492-496.
26. Chen H., Kazemier H.G., de Groote M.L., Ruiters M.H., Xu G.L., Rots M.G. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 2014, 42:1563-1574.
27. Chwang W.B., O'Riordan K.J., Levenson J.M., Sweatt J.D. ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn. Mem. 2006, 13:322-328.
28. Conti A., Fabbrini F., D'Agostino P., Negri R., Greco D., Genesio R., D'Armiento M., Olla C., Paladini D., Zannini M., Nitsch L. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics 2007, 8:268.
29. Cosgrove M.S., Boeke J.D., Wolberger C. Regulated nucleosome mobility and the histone code. Nat. Struct. Mol. Biol. 2004, 11:1037-1043.
30. Creppe C., Posavec M., Douet J., Buschbeck M. MacroH2A in stem cells: a story beyond gene repression. Epigenomics 2012, 4:221-227.
31. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. 1990, 360:263-280.
32. Day J.J., Sweatt J.D. DNA methylation and memory formation. Nat. Neurosci. 2010, 13:1319-1323.
33. Day J.J., Sweatt J.D. Cognitive neuroepigenetics: a role for epigenetic mechanisms in learning and memory. Neurobiol. Learn. Mem. 2011, 96:2-12.
34. de Groote M.L., Verschure P.J., Rots M.G. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res. 2012, 40:10596-10613.
35. De la Torre R., De Sola S., Pons M., Duchon A., de Lagran M.M., Farre M., Fito M., Benejam B., Langohr K., Rodriguez J., Pujadas M., Bizot J.C., Cuenca A., Janel N., Catuara S., Covas M.I., Blehaut H., Herault Y., Delabar J.M., Dierssen M. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol. Nutr. Food Res 2014, 58:278-288. 10.1002/mnfr.201300325.
36. Della Ragione F., Gagliardi M., D'Esposito M., Matarazzo M.R. Non-coding RNAs in chromatin disease involving neurological defects. Front. Cell. Neurosci. 2014, 8:54.
37. Deplus R., Brenner C., Burgers W.A., Putmans P., Kouzarides T., de Launoit Y., Fuks F. Dnmt3L is a transcriptional repressor that recruits histone deacetylase. Nucleic Acids Res. 2002, 30:3831-3838.
38. Down J.L. Observations on an ethnic classification of idiots. 1866. Ment. Retard. 1995, 33:54-56.
39. Eroglu B., Wang G., Tu N., Sun X., Mivechi N.F. Critical role of Brg1 member of the SWI/SNF chromatin remodeling complex during neurogenesis and neural crest induction in zebrafish. Dev. Dyn. 2006, 235:2722-2735.
40. European Medicines Agency Find Medicine - Human Medicines 2014.
41. Falahi, F., van Kruchten, M., Martinet, N., Hospers, G.A.P., Rots, M.G. Currentand upcoming approaches to exploit the reversibility of epigenetic mutations inbreast cancer (in press).
42. Falahi F., Huisman C., Kazemier H.G., van der Vlies P., Kok K., Hospers G.A., Rots M.G. Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol. Cancer. Res. 2013, 11:1029-1039.
43. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63:7563-7570.
44. Farazi T.A., Juranek S.A., Tuschl T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development 2008, 135:1201-1214.
45. Felsenfeld G., Groudine M. Controlling the double helix. Nature 2003, 421:448-453.
46. Feng J., Chang H., Li E., Fan G. Dynamic expression of de novo DNA methyltransferases Dnmt3a and Dnmt3b in the central nervous system. J. Neurosci. Res. 2005, 79:734-746.
47. Feng J., Fouse S., Fan G. Epigenetic regulation of neural gene expression and neuronal function. Pediatr. Res. 2007, 61:58R-63R.
48. Fotaki V., Dierssen M., Alcantara S., Martinez S., Marti E., Casas C., Visa J., Soriano E., Estivill X., Arbones M.L. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 2002, 22:6636-6647.
49. Gardiner K., Davisson M. The sequence of human chromosome 21 and implications for research into Down syndrome. Genome Biol. 2000, 1. REVIEWS0002.
50. Gibbons R.J., Bachoo S., Picketts D.J., Aftimos S., Asenbauer B., Bergoffen J., Berry S.A., Dahl N., Fryer A., Keppler K., Kurosawa K., Levin M.L., Masuno M., Neri G., Pierpont M.E., Slaney S.F., Higgs D.R. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. Nat. Genet. 1997, 17:146-148.
51. Graff J., Tsai L.H. Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci. 2013, 14:97-111.
52. Guo X., Williams J.G., Schug T.T., Li X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J. Biol. Chem. 2010, 285:13223-13232.
53. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell. Cycle 2011, 10:2662-2668.
54. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
55. Gupta S., Kim S.Y., Artis S., Molfese D.L., Schumacher A., Sweatt J.D., Paylor R.E., Lubin F.D. Histone methylation regulates memory formation. J. Neurosci. 2010, 30:3589-3599.
56. Hata K., Okano M., Lei H., Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 2002, 129:1983-1993.
57. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., Toyoda A., Ishii K., Totoki Y., Choi D.K., Groner Y., Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J., Schibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brant P., Scharfe M., Schon O., Desario A., Reichelt J., Kauer G., Blocker H., Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E., Haaf T., Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.L., Chromosome 21 mapping and sequencing consortium The DNA sequence of human chromosome 21. Nature 2000, 405:311-319.
58. Huang H., Rambaldi I., Daniels E., Featherstone M. Expression of the Wdr9 gene and protein products during mouse development. Dev. Dyn. 2003, 227:608-614.
59. Infantino V., Castegna A., Iacobazzi F., Spera I., Scala I., Andria G., Iacobazzi V. Impairment of methyl cycle affects mitochondrial methyl availability and glutathione level in Down's syndrome. Mol. Genet. Metab. 2011, 102:378-382.
60. Jarome T.J., Lubin F.D. Histone lysine methylation: critical regulator of memory and behavior. Rev. Neurosci. 2013, 24:375-387.
61. Jiang J., Jing Y., Cost G.J., Chiang J.C., Kolpa H.J., Cotton A.M., Carone D.M., Carone B.R., Shivak D.A., Guschin D.Y., Pearl J.R., Rebar E.J., Byron M., Gregory P.D., Brown C.J., Urnov F.D., Hall L.L., Lawrence J.B. Translating dosage compensation to trisomy 21. Nature 2013, 500:296-300.
62. Jin S., Lee Y.K., Lim Y.C., Zheng Z., Lin X.M., Ng D.P., Holbrook J.D., Law H.Y., Kwek K.Y., Yeo G.S., Ding C. Global DNA hypermethylation in down syndrome placenta. PLoS Genet. 2013, 9:e1003515.
63. Jones M.J., Farre P., McEwen L.M., Macisaac J.L., Watt K., Neumann S.M., Emberly E., Cynader M.S., Virji-Babul N., Kobor M.S. Distinct DNA methylation patterns of cognitive impairment and trisomy 21 in down syndrome. BMC Med. Genomics 2013, 6:58.
64. Joubert L., Hanson B., Barthet G., Sebben M., Claeysen S., Hong W., Marin P., Dumuis A., Bockaert J. New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4a receptor splice variant: roles in receptor targeting. J. Cell. Sci. 2004, 117:5367-5379.
65. Kahlem P., Sultan M., Herwig R., Steinfath M., Balzereit D., Eppens B., Saran N.G., Pletcher M.T., South S.T., Stetten G., Lehrach H., Reeves R.H., Yaspo M.L. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res. 2004, 14:1258-1267.
66. Kaufman P.D., Kobayashi R., Kessler N., Stillman B. The p150 and p60 subunits of chromatin assembly factor I: a molecular link between newly synthesized histones and DNA replication. Cell 1995, 81:1105-1114.
67. Kaur G., Sharma A., Xu W., Gerum S., Alldred M.J., Subbanna S., Basavarajappa B.S., Pawlik M., Ohno M., Ginsberg S.D., Wilson D.A., Guilfoyle D.N., Levy E. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome. J. Neurosci. 2014, 34:5099-5106.
68. Kerkel K., Schupf N., Hatta K., Pang D., Salas M., Kratz A., Minden M., Murty V., Zigman W.B., Mayeux R.P., Jenkins E.C., Torkamani A., Schork N.J., Silverman W., Croy B.A., Tycko B. Altered DNA methylation in leukocytes with trisomy 21. PLoS Genet. 2010, 6:e1001212.
69. Khalil A.M., Guttman M., Huarte M., Garber M., Raj A., Rivea Morales D., Thomas K., Presser A., Bernstein B.E., van Oudenaarden A., Regev A., Lander E.S., Rinn J.L. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:11667-11672.
70. Kishnani P.S., Heller J.H., Spiridigliozzi G.A., Lott I., Escobar L., Richardson S., Zhang R., McRae T. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am. J. Med. Genet. A 2010, 152A:3028-3035.
71. Korbel J.O., Tirosh-Wagner T., Urban A.E., Chen X.N., Kasowski M., Dai L., Grubert F., Erdman C., Gao M.C., Lange K., Sobel E.M., Barlow G.M., Aylsworth A.S., Carpenter N.J., Clark R.D., Cohen M.Y., Doran E., Falik-Zaccai T., Lewin S.O., Lott I.T., McGillivray B.C., Moeschler J.B., Pettenati M.J., Pueschel S.M., Rao K.W., Shaffer L.G., Shohat M., Van Riper A.J., Warburton D., Weissman S., Gerstein M.B., Snyder M., Korenberg J.R. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12031-12036.
72. Korenberg J.R., Kawashima H., Pulst S.M., Ikeuchi T., Ogasawara N., Yamamoto K., Schonberg S.A., West R., Allen L., Magenis E. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am. J. Hum. Genet. 1990, 47:236-246.
73. Korenberg J.R., Chen X.N., Schipper R., Sun Z., Gonsky R., Gerwehr S., Carpenter N., Daumer C., Dignan P., Disteche C. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:4997-5001.
74. Lee S.H., Lee S., Jun H.S., Jeong H.J., Cha W.T., Cho Y.S., Kim J.H., Ku S.Y., Cha K.Y. Expression of the mitochondrial ATPase6 gene and Tfam in Down syndrome. Mol. Cells 2003, 15:181-185.
75. Lejeune J., Turpin R., Gautier M. Mongolism; a chromosomal disease (trisomy). Bull. Acad. Natl. Med. 1959, 143:256-265.
76. Lepagnol-Bestel A.M., Zvara A., Maussion G., Quignon F., Ngimbous B., Ramoz N., Imbeaud S., Loe-Mie Y., Benihoud K., Agier N., Salin P.A., Cardona A., Khung-Savatovsky S., Kallunki P., Delabar J.M., Puskas L.G., Delacroix H., Aggerbeck L., Delezoide A.L., Delattre O., Gorwood P., Moalic J.M., Simonneau M. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Hum. Mol. Genet. 2009, 18:1405-1414.
77. Li L.C. Chromatin remodeling by the small RNA machinery in mammalian cells. Epigenetics 2013, 9:45-52.
78. Lim J.H., Lee da E., Park S.Y., Kim do J., Ahn H.K., Han Y.J., Kim M.Y., Ryu H.M. Disease specific characteristics of fetal epigenetic markers for non-invasive prenatal testing of trisomy 21. BMC Med. Genomics 2014, 7:1.
79. Liu F., Liang Z., Wegiel J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., Ramakrishna N., Gong C.X. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008, 22:3224-3233.
80. Lott I.T., Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010, 9:623-633.
81. Lu P., Roberts C.W. The SWI/SNF tumor suppressor complex: regulation of promoter nucleosomes and beyond. Nucleus 2013, 4:374-378.
82. Lubec G., Engidawork E. The brain in Down syndrome (TRISOMY 21). J. Neurol. 2002, 249:1347-1356.
83. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8A resolution. Nature 1997, 389:251-260.
84. Luger K., Dechassa M.L., Tremethick D.J. New insights into nucleosome and chromatin structure: an ordered state or a disordered affair?. Nat. Rev. Mol. Cell Biol. 2012, 13:436-447.
85. Lukiw W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007, 18:297-300.
86. Lyle R., Gehrig C., Neergaard-Henrichsen C., Deutsch S., Antonarakis S.E. Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res. 2004, 14:1268-1274.
87. Ma D.K., Jang M.H., Guo J.U., Kitabatake Y., Chang M.L., Pow-Anpongkul N., Flavell R.A., Lu B., Ming G.L., Song H. Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science 2009, 323:1074-1077.
88. Mack G.S. To selectivity and beyond. Nat. Biotechnol. 2010, 28:1259-1266.
89. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9:702-716.
90. Margot J.B., Ehrenhofer-Murray A.E., Leonhardt H. Interactions within the mammalian DNA methyltransferase family. BMC Mol. Biol. 2003, 4:7.
91. Mercer T.R., Mattick J.S. Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 2013, 20:300-307.
92. Morris K.V. RNA-directed transcriptional gene silencing and activation in human cells. Oligonucleotides 2009, 19:299-306.
93. Nagarajan R.P., Hogart A.R., Gwye Y., Martin M.R., LaSalle J.M. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics 2006, 1:e1-e11.
94. Nandakumar V., Vaid M., Katiyar S.K. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 2011, 32:537-544.
95. Nebbioso A., Carafa V., Benedetti R., Altucci L. Trials with 'epigenetic' drugs: an update. Mol. Oncol. 2012, 6:657-682.
96. Ness S., Rafii M., Aisen P., Krams M., Silverman W., Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat. Rev. Drug Discov. 2012, 11:655-656.
97. Ooi L., Wood I.C. Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet. 2007, 8:544-554.
98. Ooi S.K., Qiu C., Bernstein E., Li K., Jia D., Yang Z., Erdjument-Bromage H., Tempst P., Lin S.P., Allis C.D., Cheng X., Bestor T.H. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448:714-717.
99. Papageorgiou E.A., Karagrigoriou A., Tsaliki E., Velissariou V., Carter N.P., Patsalis P.C. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat. Med. 2011, 17:510-513.
100. Papi A., Ferreri A.M., Rocchi P., Guerra F., Orlandi M. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res. 2010, 30:535-540.
101. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., Agis-Balboa R.C., Cota P., Wittnam J.L., Gogol-Doering A., Opitz L., Salinas-Riester G., Dettenhofer M., Kang H., Farinelli L., Chen W., Fischer A. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328:753-756.
102. Pogribna M., Melnyk S., Pogribny I., Chango A., Yi P., James S.J. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am. J. Hum. Genet. 2001, 69:88-95.
103. Prandini P., Deutsch S., Lyle R., Gagnebin M., Delucinge Vivier C., Delorenzi M., Gehrig C., Descombes P., Sherman S., Dagna Bricarelli F., Baldo C., Novelli A., Dallapiccola B., Antonarakis S.E. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am. J. Hum. Genet. 2007, 81:252-263.
104. Qiu Z., Sylwestrak E.L., Lieberman D.N., Zhang Y., Liu X.Y., Ghosh A. The Rett syndrome protein MeCP2 regulates synaptic scaling. J. Neurosci. 2012, 32:989-994.
105. Ram G., Chinen J. Infections and immunodeficiency in Down syndrome. Clin. Exp. Immunol. 2011, 164:9-16.
106. Randazzo F.M., Khavari P., Crabtree G., Tamkun J., Rossant J. brg1: a putative murine homologue of the Drosophila brahma gene, a homeotic gene regulator. Dev. Biol. 1994, 161:229-242.
107. Reese B.E., Bachman K.E., Baylin S.B., Rountree M.R. The methyl-CpG binding protein MBD1 interacts with the p150 subunit of chromatin assembly factor 1. Mol. Cell. Biol. 2003, 23:3226-3236.
108. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
109. Rivenbark A.G., Stolzenburg S., Beltran A.S., Yuan X., Rots M.G., Strahl B.D., Blancafort P. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012, 7:350-360.
110. Ronan A., Fagan K., Christie L., Conroy J., Nowak N.J., Turner G. Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region. J. Med. Genet. 2007, 44:448-451.
111. Roper R.J., Reeves R.H. Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006, 2:e50.
112. Ryoo S.R., Cho H.J., Lee H.W., Jeong H.K., Radnaabazar C., Kim Y.S., Kim M.J., Son M.Y., Seo H., Chung S.H., Song W.J. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J. Neurochem. 2008, 104:1333-1344.
113. Saab B.J., Mansuy I.M. Neuroepigenetics of memory formation and impairment: the role of microRNAs. Neuropharmacology 2014, 80C:61-69.
114. Samaco R.C., Neul J.L. Complexities of Rett syndrome and MeCP2. J. Neurosci. 2011, 31:7951-7959.
115. Sanchez-Mut J.V., Huertas D., Esteller M. Aberrant epigenetic landscape in intellectual disability. Prog. Brain Res. 2012, 197:53-71.
116. Schoenherr C.J., Anderson D.J. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995, 267:1360-1363.
117. Schofield J., Isaac A., Golovleva I., Crawley A., Goodwin G., Tickle C., Brickell P. Expression of Drosophila trithorax-group homologues in chick embryos. Mech. Dev. 1999, 80:115-118.
118. Sethupathy P., Borel C., Gagnebin M., Grant G.R., Deutsch S., Elton T.S., Hatzigeorgiou A.G., Antonarakis S.E. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am. J. Hum. Genet. 2007, 81:405-413.
119. Shock L.S., Thakkar P.V., Peterson E.J., Moran R.G., Taylor S.M. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3630-3635.
120. Siddique A.N., Nunna S., Rajavelu A., Zhang Y., Jurkowska R.Z., Reinhardt R., Rots M.G., Ragozin S., Jurkowski T.P., Jeltsch A. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J. Mol. Biol. 2013, 425:479-491.
121. Sinet P.M., Theophile D., Rahmani Z., Chettouh Z., Blouin J.L., Prieur M., Noel B., Delabar J.M. Mapping of the Down syndrome phenotype on chromosome 21 at the molecular level. Biomed. Pharmacother. 1994, 48:247-252.
122. Smith D.J., Stevens M.E., Sudanagunta S.P., Bronson R.T., Makhinson M., Watabe A.M., O'Dell T.J., Fung J., Weier H.U., Cheng J.F., Rubin E.M. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet. 1997, 16:28-36.
123. Suetake I., Shinozaki F., Miyagawa J., Takeshima H., Tajima S. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J. Biol. Chem. 2004, 279:27816-27823.
124. Sun Y.M., Greenway D.J., Johnson R., Street M., Belyaev N.D., Deuchars J., Bee T., Wilde S., Buckley N.J. Distinct profiles of REST interactions with its target genes at different stages of neuronal development. Mol. Biol. Cell 2005, 16:5630-5638.
125. Sun H.J., Xu X., Wang X.L., Wei L., Li F., Lu J., Huang B.Q. Transcription factors Ets2 and Sp1 act synergistically with histone acetyltransferase p300 in activating human interleukin-12 p40 promoter. Acta Biochim. Biophys. Sin. (Shanghai) 2006, 38:194-200.
126. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
127. Tan L., Yu J.T., Hu N., Tan L. Non-coding RNAs in Alzheimer's disease. Mol. Neurobiol. 2013, 47:382-393.
128. Tejedor F., Zhu X.R., Kaltenbach E., Ackermann A., Baumann A., Canal I., Heisenberg M., Fischbach K.F., Pongs O. minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995, 14:287-301.
129. The National Center for Biotechnology Information NCBI Gene 2013.
130. U.S.National Institutes of Health ClinicalTrials.gov 2013.
131. Ueda T., Postnikov Y.V., Bustin M. Distinct domains in high mobility group N variants modulate specific chromatin modifications. J. Biol. Chem. 2006, 281:10182-10187.
132. UniProtKB/Swiss-Prot P57053 (H2BFS_HUMAN) 2013.
133. US Food Drug Administration Drugs@FDA: FDA Approved Drug Products 2014.
134. Valenti D., Tullo A., Caratozzolo M.F., Merafina R.S., Scartezzini P., Marra E., Vacca R.A. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. Biochem. J. 2010, 431:299-310.
135. Valenti D., De Rasmo D., Signorile A., Rossi L., de Bari L., Scala I., Granese B., Papa S., Vacca R.A. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. Biochim. Biophys. Acta 2013, 1832:542-552.
136. van den Berg A., Mols J., Han J. RISC-target interaction: cleavage and translational suppression. Biochim. Biophys. Acta 2008, 1779:668-677.
137. Veerappan C.S., Sleiman S., Coppola G. Epigenetics of Alzheimer's disease and frontotemporal dementia. Neurotherapeutics 2013, 10:709-721.
138. Verreault A., Kaufman P.D., Kobayashi R., Stillman B. Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell 1996, 87:95-104.
139. Villard L., Toutain A., Lossi A.M., Gecz J., Houdayer C., Moraine C., Fontes M. Splicing mutation in the ATR-X gene can lead to a dysmorphic mental retardation phenotype without alpha-thalassemia. Am. J. Hum. Genet. 1996, 58:499-505.
140. Wallace D.C., Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion 2010, 10:12-31.
141. Wang X., Zhao Y., Zhang X., Badie H., Zhou Y., Mu Y., Loo L.S., Cai L., Thompson R.C., Yang B., Chen Y., Johnson P.F., Wu C., Bu G., Mobley W.C., Zhang D., Gage F.H., Ranscht B., Zhang Y.W., Lipton S.A., Hong W., Xu H. Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome. Nat. Med. 2013, 19:473-480.
142. Weeber E.J., Sweatt J.D. Molecular neurobiology of human cognition. Neuron 2002, 33:845-848.
143. Weng Y.L., An R., Shin J., Song H., Ming G.L. DNA modifications and neurological disorders. Neurotherapeutics 2013, 10:556-567.
144. Wilcock D.M. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr. Gerontol. Geriatr. Res. 2012, 2012:170276.
145. Wiseman F.K., Alford K.A., Tybulewicz V.L., Fisher E.M. Down syndrome-recent progress and future prospects. Hum. Mol. Genet. 2009, 18:R75-R83.
146. Yang E.J., Ahn Y.S., Chung K.C. Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J. Biol. Chem. 2001, 276:39819-39824.
147. Zentner G.E., Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat. Struct. Mol. Biol. 2013, 20:259-266.
148. Zhang R.R., Cui Q.Y., Murai K., Lim Y.C., Smith Z.D., Jin S., Ye P., Rosa L., Lee Y.K., Wu H.P., Liu W., Xu Z.M., Yang L., Ding Y.Q., Tang F., Meissner A., Ding C., Shi Y., Xu G.L. Tet1 regulates adult hippocampal neurogenesis and cognition. Cell. Stem Cell. 2013, 13:237-245.
149. Zigman W.B., Lott I.T. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment. Retard. Dev. Disabil. Res. Rev. 2007, 13:237-246.